DAND5 Polyclonal Antibody (AN006820L)
For research use only.
| Verified Samples | Verified Samples in WB: Mouse testis |
| Dilution | WB 1:500-1:1000 |
| Isotype | IgG |
| Host | Rabbit |
| Reactivity | Mouse |
| Applications | WB |
| Clonality | Polyclonal |
| Immunogen | Recombinant Human DAND5 protein expressed by E.coli |
| Abbre | DAND5 |
| Synonyms | CER, GREM, Dand, CKTSF1B, CER2, CKTSF1B3, GREM3, SP1, DAND5 |
| Swissprot | |
| Calculated MW | 20 kDa |
| Observed MW |
20 kDa
Western blotting is a method for detecting a certain protein in a complex sample based on the specific binding of antigen and antibody. Different proteins can be divided into bands based on different mobility rates. The mobility is affected by many factors, which may cause the observed band size to be inconsistent with the expected size. The common factors include: 1. Post-translational modifications: For example, modifications such as glycosylation, phosphorylation, methylation, and acetylation will increase the molecular weight of the protein. 2. Splicing variants: Different expression patterns of various mRNA splicing bodies may produce proteins of different sizes. 3. Post-translational cleavage: Many proteins are first synthesized into precursor proteins and then cleaved to form active forms, such as COL1A1. 4. Relative charge: the composition of amino acids (the proportion of charged amino acids and uncharged amino acids). 5. Formation of multimers: For example, in protein dimer, strong interactions between proteins can cause the bands to be larger. However, the use of reducing conditions can usually avoid the formation of multimers. If a protein in a sample has different modified forms at the same time, multiple bands may be detected on the membrane. |
| Cellular Localization | Secreted |
| Concentration | 1 mg/mL |
| Buffer | PBS with 0.05% proclin 300, 1% protective protein and 50% glycerol,pH7.4 |
| Purification Method | Antigen Affinity Purification |
| Conjugation | Unconjugated |
| Storage | Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles. |
| Shipping | The product is shipped with ice pack, upon receipt, store it immediately at the temperature recommended. |
| background | COCO, also known as DAND5, Dante, and CKTSF1B3, is a member of the DAN Domain family of BMP antagonists that includes DAN (DAND1), Gremlin/Drm (DAND2), PRDC (Protein Related to Dan and Cerberus; DAND3), and Cerberus (DAND4). DAN family members contain a cysteine-knot domain that is homologous to that found in other TGF-beta superfamily ligands. BMPs play important roles in tissue morphogenesis and development processes. The human COCO cDNA encodes a 189 amino acid (aa) precursor with a 22 aa signal sequence. COCO has eight Cys residues in the cysteine-knot which places it in the CAN subfamily of BMP antagonists along with the other DAN family proteins. Human COCO shares 60% and 24% aa sequence identity with mouse and Xenopus COCO, respectively. It shares 17%, 20%, 25%, and 22% aa sequence identity with human DAN, Gremlin, PRDC, and Cerberus, respectively. In Xenopus embryonal development, COCO is expressed by pluripotent ectodermal cells. Expression is abruptly downregulated prior to gastrulation, and the loss of ectodermal cell pluripotency is coincident with COCO downregulation. COCO binds and inhibits Xnr1, BMP-4, Activin, and Wnt-8. In mouse, COCO expression is elevated on the right side of Henson’s node at the early somite stage, in contrast to the left side expression of Nodal. COCO may cooperate with Nodal in gastrulation and embryonic left-right axis formation. |
Other Clones
{{antibodyDetailsPage.numTotal}} Results
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
Other Formats
{{formatDetailsPage.numTotal}} Results
Unconjugated
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
-
IF：{{item.impact}}
Journal：{{item.journal}} ({{item.year}})
DOI：{{item.doi}}Reactivity：{{item.species}}
Sample Type：{{item.organization}}
-
Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}
